Fig. 2: Prevalence of SOX2&NTRK2 in tumor samples from NPC patients.

A UMAP representation of different cell types in a published NPC dataset. B UMAPs displaying the expression levels of SOX2 and other surface markers in this published NPC dataset. C Dot plot illustrating the expression levels of SOX2 and other surface markers in malignant cells from various published NPC datasets. D Immunostaining images demonstrating the detection of SOX2 and TrkB in patient slides. E RNA-scope images revealing different abundances of SOX2 and NTRK2 in patients with long survival (over 150 weeks) or short survival (less than 50 weeks). SOX2 is labeled in red, NTRK2 is labeled in green, and nuclei are labeled in blue. F Box plots presenting the quantitative results of RNA-scope; the normalized expression levels of SOX2 and NTRK2 in long and short survival patient groups. G Scatter plot displaying the correlation between SOX2 and NTRK2 using a bulk RNA-seq dataset. Patients were separated into two groups based on SOX2/NTRK2 co-expression. H Kaplan–Meier progression-free survival curves for the two groups of patients with high SOX2/NTRK2 co-expression or low co-expression.